Chemotherapy-induced nausea and vomiting (CINV) - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: C806B83925A5EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Chemotherapy-induced nausea and vomiting (CINV) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Chemotherapy-induced nausea and vomiting (CINV) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Chemotherapy-induced nausea and vomiting (CINV) Understanding

The DelveInsight Chemotherapy-induced nausea and vomiting (CINV) epidemiology report gives a thorough understanding of the Chemotherapy-induced nausea and vomiting (CINV) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Chemotherapy-induced nausea and vomiting (CINV) in the US, Europe, and Japan. The report covers the detailed information of the Chemotherapy-induced nausea and vomiting (CINV) epidemiology scenario in seven major countries (US, EU5, and Japan).

Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Perspective by DelveInsight

The Chemotherapy-induced nausea and vomiting (CINV) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Chemotherapy-induced nausea and vomiting (CINV) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Chemotherapy-induced nausea and vomiting (CINV) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Chemotherapy-induced nausea and vomiting (CINV) Detailed Epidemiology Segmentation

The Chemotherapy-induced nausea and vomiting (CINV) epidemiology covered in the report provides historical as well as forecasted Chemotherapy-induced nausea and vomiting (CINV) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Chemotherapy-induced nausea and vomiting (CINV) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Chemotherapy-induced nausea and vomiting (CINV) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Report and Model provide an overview of the global trends of Chemotherapy-induced nausea and vomiting (CINV) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Chemotherapy-induced nausea and vomiting (CINV) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Chemotherapy-induced nausea and vomiting (CINV)
• The report provides the segmentation of the Chemotherapy-induced nausea and vomiting (CINV) epidemiology

Report Highlights

• 11-year Forecast of Chemotherapy-induced nausea and vomiting (CINV) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Chemotherapy-induced nausea and vomiting (CINV)
• Cases of Chemotherapy-induced nausea and vomiting (CINV) by Mutation Types
• Chemotherapy-induced nausea and vomiting (CINV) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chemotherapy-induced nausea and vomiting (CINV)?
• What are the key findings pertaining to the Chemotherapy-induced nausea and vomiting (CINV) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Chemotherapy-induced nausea and vomiting (CINV) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Chemotherapy-induced nausea and vomiting (CINV)?
• What are the currently available treatments of Chemotherapy-induced nausea and vomiting (CINV)?

Reasons to buy

The Chemotherapy-induced nausea and vomiting (CINV) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Chemotherapy-induced nausea and vomiting (CINV) market
• Quantify patient populations in the global Chemotherapy-induced nausea and vomiting (CINV) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chemotherapy-induced nausea and vomiting (CINV) therapeutics in each of the markets covered
• Understand the magnitude of Chemotherapy-induced nausea and vomiting (CINV) population by its epidemiology
• The Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)

3. CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Chemotherapy-induced nausea and vomiting (CINV) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Chemotherapy-induced nausea and vomiting (CINV) Treatment and Management
6.2. Chemotherapy-induced nausea and vomiting (CINV) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in 7MM (2019-2032)
Table 2: Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in the United States (2019-2032)
Table 4: Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in Germany (2019-2032)
Table 6: Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in France (2019-2032)
Table 8: Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in Italy (2019-2032)
Table 10: Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in Spain (2019-2032)
Table 12: Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in the United Kingdom (2019-2032)
Table 14: Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in Japan (2019-2032)
Table 16: Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in 7MM (2019-2032)
Figure 2 Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in the United States (2019-2032)
Figure 4 Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in Germany (2019-2032)
Figure 6 Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in France (2019-2032)
Figure 8 Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in Italy (2019-2032)
Figure 10 Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in Spain (2019-2032)
Figure 12 Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Chemotherapy-induced nausea and vomiting (CINV) Epidemiology in Japan (2019-2032)
Figure 16 Chemotherapy-induced nausea and vomiting (CINV) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report